Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Safety of CHF5993 in Healthy Subjects
NCT05830071Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma and chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Heart rate-corrected QT interval based on Fridericia's correction. Started Mar 2023; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05830071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830071.